Novartis Updates Anti-Bribery Policy Following Settlements
Harry Cassin identifies several highlights from Novartis' anti-bribery policy, which the company updated after paying nearly $350 million to resolve FCPA allegations over activities in Greece, Vietnam, and South Korea.
🔒 Members Only · Compliance & Enforcement BriefYou’ve reached the member portion of this brief.Members read the full analysis and the source documents in every Brief, six days a week.